Company news
Xenetic Biosciences, Inc. (NASDAQ:XBIO) news
Xenetic Biosciences, Inc. news releases on 6ix. Latest, Mar 23, 2023: Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business…
Press releases — page 2
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
March 22, 2023
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
March 15, 2023
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
January 16, 2023
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
January 4, 2023
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
November 15, 2022
Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
October 10, 2022
Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board
October 3, 2022
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022
Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022
Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
August 1, 2022
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
July 6, 2022
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
June 1, 2022
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022
Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022
Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
April 26, 2022
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
March 22, 2022
Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
November 11, 2021
Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent
September 8, 2021
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 7, 2021
Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021
Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market
July 27, 2021
Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market
July 25, 2021
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results
May 11, 2021
Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit
May 9, 2021
Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)
March 28, 2021
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
March 2, 2021
Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology
February 15, 2021
Xenetic Biosciences, Inc. to Present at NobleCon17
January 13, 2021
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
January 4, 2021
Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
December 13, 2020
Xenetic Biosciences, Inc. Announces $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
December 9, 2020
Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology
December 8, 2020
Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 12, 2020
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 6th Annual Israel Conference
November 4, 2020
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 8, 2020
Xenetic Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 12, 2020
Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Two Key Appointments
July 29, 2020
Xenetic Biosciences, Inc. Provides Development Update for Its Personalized CAR T Platform Technology, XCART(TM)
June 30, 2020
Xenetic Biosciences, Inc. Announces Collaboration with Pharmsynthez and Multiple Academic Institutions in Russia and Belarus to Advance Development of XCART(TM) Platform
June 15, 2020
Xenetic Biosciences, Inc. to Present at the Virtual Investor Fireside Chat Series
June 7, 2020
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART(TM) Platform
May 18, 2020
Xenetic Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 13, 2020
Xenetic Biosciences, Inc. to Present at the April 2020 Virtual Investor Summit
April 14, 2020
Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update
March 26, 2020
Xenetic Biosciences' Webcast Replay from Noble Capital Markets' 16th Annual Investor Conference Presentation Now Available
February 26, 2020
Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board
February 25, 2020
Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board
February 12, 2020
Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference
February 10, 2020
Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 14, 2019